Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM561 in pediatric malignant glioma and solid tumors
NCT04299191Phase 2Recruiting
- Sponsor
- Laminar Pharma
- Start
- Sep 2020
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 2-hydroxyoleic acid in glioma, solid tumor, sponsored by Laminar Pharma. Started Sep 2020; status: recruiting.
02
Drugs
2-hydroxyoleic acid
03
Conditions
gliomasolid tumor
Beyond the preview
Go deeper on NCT04299191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04299191.